Related Experiment Videos

Efficacy of vancomycin plus tobramycin as antiperitonitis regimen for patients on CAPD

V Vargemezis1, E Thodis, P Pasadakis

  • 1Democritus University of Thrace, General District Hospital, Alexadroupolis, Greece.

Insights

Intraperitoneal Vancomycin and Tobramycin effectively treated peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients. This antibiotic regimen demonstrated a low recurrence rate and no observed side effects, indicating its suitability for CAPD peritonitis management.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Pharmacology

Background:

  • Peritonitis is a significant complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
  • Effective antibiotic treatment is crucial for managing CAPD-related peritonitis and preventing recurrence.

Purpose of the Study:

  • To evaluate the efficacy and safety of intraperitoneal Vancomycin and Tobramycin for treating CAPD peritonitis.
  • To determine the recurrence rate and side effects associated with this combined antibiotic regimen.

Main Methods:

  • A total of 55 episodes of peritonitis in 35 CAPD patients were treated between October 1985 and August 1989.
  • The treatment involved intraperitoneal (i.p.) administration of Vancomycin and Tobramycin, with specific loading and maintenance doses over a 10-day period.
  • Antibiotic selection (Vancomycin, Tobramycin, or both) was guided by antibiogram results and culture findings.

Main Results:

  • A low recurrence rate of peritonitis was observed in 3 out of 55 episodes (5.4%).
  • No adverse side effects were reported during the course of the antibiotic therapy.
  • The combined regimen showed effectiveness in clearing infections and preventing relapse.

Conclusions:

  • Intraperitoneal Vancomycin and Tobramycin represent an appropriate and safe anti-peritonitis regimen for CAPD patients.
  • This therapeutic approach offers a favorable outcome with minimal risk of recurrence and side effects.
  • The study supports the use of this combination therapy in the clinical management of CAPD peritonitis.

Related Concept Videos